TGFB2 and neoplasm: Targeting Ligands by either monoclonal antibodies (Lerdelimumab (CAT-152/Trabio), Metelimumab (CAT-192), GC-1008 (Cambridge Antibody Technology) or ASO technology was mainly developed for treatment of fibrotic disorders and in the field of oncology (TGFβ2 antisense modified allogenic tumor cell vaccine (Lucanix, NovaRx), AP-12009 (Trabedersen) and AP-11014 (Antisense Pharma)) [43].